地點

• 先進的醫療和研究基礎設施
• 針對臨床試驗支出，可獲得高達 43.5%的政府費用返還
• 簡單快速的監管路徑

點擊查看更多相關資訊

• 歐洲擁有蓬勃發展的生物科技產業，以及立基於歐洲的 CRO EastHORN 加入 Novotech，改善了我們與該客戶群的接觸管道。
• 由於終端市場的商業規模及龐大患者族群的可用性 (尤其是在中歐和東歐)，使得歐洲成為一個極具吸引力的臨床研發區域。
• 歐洲一直是生物相似性藥品監管的領導者，並且許多此類試驗皆於歐洲進行。

點擊查看更多相關資訊

• Very large, homogenous population
• Strong focus of NMPA (previously CFDA) on shortening regulatory timelines
• Largest clinical trial hub in Asia, with over 17,000 active investigators

點擊查看更多相關資訊

• Large treatment-naïve population
• High disease population load
• The clinical activity grew by over 40% in 2018 on the back of regulatory pathway improvements
• About 1,800 investigators have participated on a minimum of 5 studies

點擊查看更多相關資訊

• Multiethnic Asian population
• Streamlined regulatory system and Strong govt. support 
• Quick start-up timelines
• Low patient costs and IRB fees

點擊查看更多相關資訊

• High-quality research, facilities and equipment
• Fast set-up and approval times
• Sponsor can claim R&D cash refund

點擊查看更多相關資訊

• Large treatment-naïve population
• Low costs
• Overall good level of English

點擊查看更多相關資訊

• Multiethnic Asian population 
• Regional clinical research hub
• Efficient regulatory process and good infrastructure

點擊查看更多相關資訊

• Diverse Patient Population
• Efficient Regulatory Environment
• Cost-Effectiveness 

點擊查看更多相關資訊

• Homogenous and concentrated population 
• High quality medical services and excellent infrastructure
• The most active Asian country in clinical research after China, with over 400 sites opened by biopharmas companies in 2018

點擊查看更多相關資訊

• Large homogenous population 
• High prevalence of communicable diseases
• Efficient regulatory system
• Low operational cost

點擊查看更多相關資訊

• Following the acquisition and integration of a long standing full-service CRO partner, Novotech now provides services across the United States"

點擊查看更多相關資訊